1) Ambrogio C, Voena C, Manazza AD, Piva R, Riera L, Barberis L, Costa C, Tarone G, Defilippi P, Hirsch E, Erba EB, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood. 2005 Dec 1. IF: 13.164
2) Piva R, Chiarle R, Manazza AD, Taulli R, Simmons W, Ambrogio C, D'Escamard V, Pellegrino E, Ponzetto C, Palestro G, Inghirami G. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood. 2006 Jan 15. IF: 13.164
3) Voena C, Conte C, Ambrogio C, Boeri Erba E, Boccalatte F, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res. 2007 May 1. IF: 9.13
4) Berto G, Camera P, Fusco C, Imarisio S, Ambrogio C, Chiarle R, Silengo L, Di Cunto F. The Down syndrome critical region protein TTC3 inhibits neuronal differentiation via RhoA and Citron kinase. J Cell Sci. 2007 Jun 1. IF: 4.401
5) Costa C, Barberis L, Ambrogio C, Manazza AD, Patrucco E, Azzolino O, Nielssen P, Circolo E, Altruda F, Prestwich G, Chiarle R, Wymann M, Ridley A, Hirsch E. Constitutive elevation of phosphoinositide 3-Kinase γ activity in mice does not increase tumor susceptibility but reveals a negative feedback loop regulating Rac during leukocyte chemotaxis. PNAS 2007 Sept 4. IF: 9.661
6) Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008 Jan. IF: 42.784
7) Chiarle R, Martinengo C, Mastini C, Ambrogio C, D’Escamard V, Forni G, Inghirami G. Anaplastic Lymphoma Kinase is an effective oncoantigen for lymphoma vaccination. Nat Med 2008 Jun. IF: 32.621
8) Crosetto N, Bienko M, Hibbert RG, Perica T, Ambrogio C, Kensche T, Hofmann K, Sixma TK, Dikic I. Human WRNIP1 is localized in replication factories in a UBZ-dependent manner. J Biol Chem. 2008 Dec 12. IF: 4.125
9) Ambrogio C, Voena C, Manazza AD, Martinengo C, Costa C, Kirchhausen T, Hirsch E, Inghirami G and Chiarle R. Anaplastic Lymphoma Kinase controls cell shape and growth of Anaplastic Large Cell Lymphoma through Cdc42. Cancer Res 2008 Nov 1. IF: 9.13
10) Barberis L, Pasquali C, Bertschy-Meier D, Cuccurullo A, Costa C, Ambrogio C, Vilbois F, Chiarle R, Wymann M, Altruda F, Rommel C, Hirsch E. Leukocyte transmigration is modulated by chemokine-mediated, PI3Kγ-dependent phosphorylation of vimentin. European Journal of Immunology 2009 Apr. IF: 4.248
11) Gonzalo P, Guadamillas MC, Hernández-Riquer MV, Pollán A, Grande-García A, Bartolomé RA, Vasanji A, Ambrogio C, Chiarle R, Teixidó J, Risteli J, Apte SS, del Pozo MS, and Arroyo AG. Membrane type 1-matrix metalloproteinase contributes to macrophage fusion through the regulation of the Rac1 signaling pathway. Dev Cell. 2010 Jan 19. IF: 9.616
12) Ambrogio C, Martinengo C, Voena C, Tondat F, Francia di Celle P, Inghirami G and Chiarle R. NPM-ALK oncogenic tyrosine kinase controls T cell identity by transcriptional and epigenetic silencing in lymphoma cells. Cancer Res 2009 Nov 15. IF: 9.13
13) Riera L, Lasorsa E, Ambrogio C, Surrenti N, Voena C, Chiarle R. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. J Biol Chem. 2010 Aug 20. IF: 4.125
14) Boselli D, Ragimbeau J, Orlando L, Cappello P, Capello M, Ambrogio C, Chiarle R, Marsili G, Battistini A, Giovarelli M, Pellegrini S, Novelli F. Expression of IFNgammaR2 mutated in a dileucine internalization motif reinstates IFNgamma signaling and apoptosis in human T lymphocytes. Immunol Lett. 2010 2010 Nov 30. IF: 1.85
15) Di Paolo D*, Ambrogio C*, Pastorino F, Brignole C, Martinengo C, Carosio R, Loi M, Pagnan G, Emionite L, Cilli M, Ribatti D, Allen TM, Chiarle R, Ponzoni M, Perri P. Selective Therapeutic Targeting of the Anaplastic Lymphoma Kinase With Liposomal siRNA Induces Apoptosis and Inhibits Angiogenesis in Neuroblastoma. Mol Ther. 2011 Aug 9. *equally contributed. IF: 6.938
16) Bosio Y, Berto G, Camera P, Bianchi F, Ambrogio C, Claus P, Di Cunto F. PPP4R2 regulates neuronal cell differentiation and survival, functionally cooperating with SMN. Eur J Cell Biol. 2012 Aug. IF: 5.22
17) Voena C, Di Giacomo F, Panizza E, D'Amico L, Boccalatte FE, Pellegrino E, Todaro M, Recupero D, Tabbò F, Ambrogio C, Martinengo C, Bonello L, Pulito R, Hamm J, Chiarle R, Cheng M, Ruggeri B, Medico E, Inghirami G. The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. Oncogenesis. 2013 Apr 8. IF: 4.722
18) Piazza R, Magistroni V, Mogavero A, Andreoni F, Ambrogio C, Chiarle R, Mologni L, Bachmann PS, Lock RB, Collini P, Pelosi G, Gambacorti-Passerini C. Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex. Neoplasia. 2013 May. IF: 5.006
19) Martinengo C, Poggio T, Menotti M, Scalzo MS, Mastini C, Ambrogio C, Pellegrino E, Riera L, Piva R, Ribatti D, Pastorino F, Perri P, Ponzoni M, Wang Q, Voena C, Chiarle R. ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis. Cancer Res. 2014 Sep 5. IF: 9.13
20) Ambrogio C, Carmona FJ, Vidal A, Falcone M, Nieto P, Romero OA, Puertas S, Vizoso M, Nadal E, Poggio T, Sánchez-Céspedes M, Esteller M, Mulero F, Voena C, Chiarle R, Barbacid M, Santamaría D, Villanueva A. Modeling Lung Cancer Evolution and Preclinical Response by Orthotopic Mouse Allografts. Cancer Res. 2014 Sep 12. IF: 9.13
21) Ambrogio C, Stern P, Scuoppo C, Kranz H, Barbacid M, Santamaría D. Lentiviral-based approach for the validation of cancer therapeutic targets in vivo. Biotechniques. 2014 Oct 1. IF: 2.098
22) Blasco RB, Karaca E, Ambrogio C, Cheong TC, Karayol E, Minero VG, Voena C, Chiarle R. Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology. Cell Rep. 2014 Nov 20. IF: 8.282
23) Lopez-Contreras AJ, Specks J, Barlow JH, Ambrogio C, Desler C, Vikingsson S, Rodrigo-Perez S, Green H, Rasmussen LJ, Murga M, Nussenzweig A, Fernandez-Capetillo O. Increased Rrm2 gene dosage reduces fragile site breakage and prolongs survival of ATR mutant mice. Genes Dev. 2015 Apr 1. IF: 9.413
24) García-Beccaria M, Martínez P, Méndez-Pertuz M, Martínez S, Blanco-Aparicio C, Cañamero M, Mulero F, Ambrogio C, Flores JM, Megias D, Barbacid M, Pastor J, Blasco MA. Therapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damage. EMBO Mol Med. 2015 May 13. IF: 9.249
25) Voena C, Menotti M, Mastini C, Di Giacomo F, Longo DL, Castella B, Merlo ME, Ambrogio C, Wang Q, Minero VG, Poggio T, Martinengo C, D'Amico L, Panizza E, Mologni L, Cavallo F, Altruda F, Butaney M, Capelletti M, Inghirami G, Jänne PA, Chiarle R. Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. Cancer Immunol Res. 2015 Sep 29. IF: 9.188
26) Ambrogio C, Cámara JA, Nieto P, Santamaría D, Mulero F. Analysis of Murine Lung Tumors by Micro PET-CT Imaging. Bio-protocol, 2015 December.
27) Ceccon M, Merlo ME, Mologni L, Poggio T, Varesio LM, Menotti M, Bombelli S, Rigolio R, Manazza AD, Di Giacomo F, Ambrogio C, Giudici G, Casati C, Mastini C, Compagno M, Turner SD, Gambacorti-Passerini C, Chiarle R, Voena C. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. Oncogene. 2016 Jul 21. IF: 6.854
28) Choudhari R, Minero VG, Menotti M, Pulito R, Brakebusch C, Compagno M, Voena C, Ambrogio C*, Chiarle R*. Redundant and non-redundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice. Blood. 2016 Jan 8. *Co-last author. IF: 13.164
29) Ambrogio C*, Gómez-López G, Falcone M, Villanueva A, Crosetto N, Blasco R, Sánchez-Céspedes M, Ren X, Wang Z, Ding K, Serrano M, Hidalgo M, Santamaría D*, Barbacid M*. Combined inhibition of Ddr1 and Notch signaling as an effective therapeutic strategy for K-Ras-driven/p53-null lung adenocarcinomas. Nat Med. 2016 Feb 8. *Co-corresponding author. IF: 32.621
(Referred by Research Watch in Cancer Discovery: Dual Therapy with DDR1 and Notch Inhibitors Kills KRAS-Mutant Lung Tumors. Cancer Discov. 2016 Feb 18.)
30) Ambrogio C*, Nadal E, Villanueva A, Gómez-López G, Cash TP, Barbacid M, Santamaría D. KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy. ESMO Open. 2016 Sept 1. *Corresponding author.
31) Ambrogio C*, Barbacid M, Santamaría D*. In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma. Oncogene. 2016 Oct 24. *Co-corresponding author. IF: 6.854
32) Ambrogio C, Santamaria D. DDR1 and Notch: a multifaceted synergy. Translational Cancer Research. 2016 Dec. IF: 1.757.
33) Compagno M, Wang Q, Pighi C, Cheong TC, Meng FL, Poggio T, Yeap LS, Karaca E, Blasco RB, Langellotto F, Ambrogio C, Voena C, Wiestner A, Kasar SN, Brown JR, Sun J, Wu CJ, Gostissa M, Alt FW, Chiarle R. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells. Nature. 2017 Feb 23. IF: 40.137
34) Kohler J, Catalano M, Ambrogio C. Back to the bench? MEK and ERK inhibitors for the treatment of KRAS mutant lung adenocarcinoma. Curr Med Chemistry. 2017 May 29. IF: 3.469
35) Zeng M, Lu J, Li L, Feru F, Quan C, Gero TW, Ficarro SB, Xiong Y, Ambrogio C, Paranal RM, Catalano M, Shao J, Wong KK, Marto JA, Fischer ES, Jänne PA, Scott DA, Westover KD, Gray NS. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. Cell Chem Biol. 2017 Jul. IF: 5.592
36) Nieto P, Ambrogio C, de Esteban L, Gómez-López G, Blasco MT, Yao Z, Marais R, Rosen N, Chiarle R, Pisano DG, Barbacid M, Santamaría D. A B-Raf kinase inactive mutant induces lung adenocarcinoma. Nature. 2017 Aug 2. IF: 40.137
37) Ambrogio C*, Köhler J, Zhou ZW, Wang H, Paranal R, Li J, Capelletti M, Caffarra C, Li S, Lv Q, Gondi S, Hunter JC, Lu J, Chiarle R, Santamaría D, Westover KD, Jänne PA*. KRAS dimerization impacts MEK inhibitor sensitivity and oncogenic activity of mutant KRAS. Cell. 2018 Jan 4. *Co-corresponding author. IF: 31.398
38) Ambrogio C, Darbo E, Lee SW, Santamaria D. A putative role for Discoidin Domain Receptor 1 in cancer chemoresistance. Cell Adhesion & Migration, 2018 March 5. IF: 3.566
39) Abravanel DL, Nishino M, Sholl LM, Ambrogio C, Awad MM. An acquired NRAS Q61K mutation in BRAF V600E-mutant lung adenocarcinoma resistant to dabrafenib plus trametinib. J Thorac Oncol. 2018 Apr 6. IF: 10.336
40) Li S, Liu S, Deng J, Akbay EA, Hai J, Ambrogio C, Zhang L, Zhou F, Jenkins RW, Adeegbe DO, Gao P, Wang X, Paweletz CP, Herter-Sprie GS, Chen T, Gutierrez Quiceno L, Zhang Y, Merlino AA, Quinn MM, Zeng Y, Yu X, Liu Y, Fan L, Aguirre AJ, Barbie DA, Yi X, Wong KK. Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS G12C-Driven Mouse Model of Lung Cancer. Clin Cancer Res. 2018 Jun 26. IF: 10.199
41) Kobayashi Y, Ambrogio C, Mitsudomi T. Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights. Transl Lung Cancer Res Jul 2018. IF: 4.806
42) Dagogo-Jack I‚ Martinez P, Yeap BY, Ambrogio C, Ferris LA, Lydon CA, Nguyen T, Jessop N, Iafrate JA, Johnson BE, Lennerz JK, Shaw AT, Awad MM. Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-Mutant Lung Cancer. Clin Cancer Res. 2018 Sep 17. pii: clincanres.2062.2018. doi: 10.1158/1078-0432.CCR-18-2062. IF: 10.199
43) Menotti M, Ambrogio C, Cheong TC, Pighi C, Mota I, Cassel SH, Compagno M, Wang Q, Dall’Olio R, Minero V, Poggio T, Sharma GG, Patrucco E, Mastini C, Choudhari R, Pich A, Zamo A, Piva R, Giliani S, Mologni L, Collings CK, Kadoch C, Gambacorti-Passerini C, Notarangelo LD, Anton ID, Voena C, Chiarle R. Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. Nat Med. 2018 Dec 3. https://doi.org/10.1038/s41591-018-0262-9 IF: 32.621
44) Wang H, Lv Q, Xu Y, Cai Z, Zheng J, Chen X, Dai Y, Jänne PA, Ambrogio C* and Köhler J*. An integrative pharmacogenomics analysis identifies CK2 alpha as a promising therapeutic target in KRAS(G12C) mutant lung cancer. EBioMedicine. 2019 Nov;49:106-117. doi: 10.1016/j.ebiom.2019.10.012. Epub 2019 Oct 23. *Co-last author. IF: 6.68